25 January

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 02:22
  [Comment] Diabetes registries and high-quality diabetes care - Kamlesh Khunti, Chantal Mathieu, Bart Torbeyns, Stefano Del Prato, Robert Heine, EUDF Strategic Forum Data and Registries Lancet Diab Endocrinol
  Diabetes registries have been established in many countries following recommendations of the St Vincent Declaration to help improve quality of care for diabetes.1 Diabetes registries can help measure and compare outcomes, and highlight variations in care for quality improvement. Well (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [Correspondence] Insulin products and patents in the USA in 2004, 2014, and 2020: a cross-sectional study - Victor L Van de Wiele, Aaron S Kesselheim, David Beran, Jonathan J Darrow Lancet Diab Endocrinol
  To treat diabetes, one of the most prevalent diseases globally and in the USA,1 the US Food and Drug Administration (FDA) has approved a wide range of synthetic insulin products since the early 1980s. Despite this range of products, access to insulin remains challenging in part due to product (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [In Focus] May Ng: a lifetime commitment to children - Carl Power Lancet Diab Endocrinol
  May Ng says that, growing up in Malaysia, she always knew what she wanted to be: “As a small child, I would say paediatrician, not doctor”. She loved looking after her younger sister and cousins. Ng has turned her affection for children into a (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [In Focus] Diabetes educators: rewriting the narrative - Marta Koch, Parizad Avari Lancet Diab Endocrinol
  “We are a large family”, agree Prashanth Mani, Lakshminarayana Varimadugu, and Sridhar Rajamohan, who are diabetes educators in India and who live with type 1 diabetes themselves. Diabetes care in low-income and middle-income countries (LMICs) entails many challenges. Delayed diagnosis, (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [Corrections] Correction to Lancet Diabetes Endocrinol 2022; 10: 859–68 Lancet Diab Endocrinol
  Haqq AM, Chung WK, Dollfus H, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [Articles] Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial - Margaretha M Visser, Sara Charleer, Steffen Fieuws, Christophe De Block, Robert Hilbrands, Liesbeth Van Huffel, Toon Maes, Gerd Vanhaverbeke, Eveline Dirinck, Nele Myngheer, Chris Vercammen, Frank Nobels, Bart Keymeulen, Chantal Mathieu, Pieter Gillard Lancet Diab Endocrinol
  Glycaemic control and hypoglycaemia worry improved significantly up to 24 months after switching from isCGM without alerts to rtCGM with alerts, supporting the use of rtCGM in the care of adults with type 1 diabetes. (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [Editorial] The voices of lived experience in diabetes and endocrinology - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  Patients are at the heart of medicine. Thankfully, the world is filled with caring professionals who both improve and save lives every day, despite the incredible pressures that they and health systems are under. There is also some reassurance and comfort in knowing that most health-care (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [Comment] Clinical use of continuous glucose monitoring in type 1 diabetes - Kirsten Nørgaard, Ulrik Pedersen-Bjergaard Lancet Diab Endocrinol
  Advances in diabetes technology over the past 2 decades have provided treatment solutions that are now widely adopted in the management of type 1 diabetes. One such example is the integration of continuous glucose monitoring (CGM) systems as part of the standard of care for type 1 diabetes.1 (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))